|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15371538153915401541154215431544154515461547...15771578» |
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Pazopanib for Metastatic Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Mar 10, 2015
P2, N=19, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Mar 2015 --> Mar 2016
- Clinical: Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=20, Recruiting, Sponsor: University of Southern California
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Trial primary completion date: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - Mar 10, 2015
P1, N=50, Active, not recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Feb 2015
- | onalespib (AT13387) / Otsuka
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST (clinicaltrials.gov) - Mar 10, 2015
P2, N=26, Completed, Sponsor: Astex Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Feb 2015 Active, not recruiting --> Completed | N=36 --> 26 | Trial primary completion date: May 2014 --> Apr 2013
- doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 9, 2015
P1, N=36, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=36 --> 26 | Trial primary completion date: May 2014 --> Apr 2013 Trial primary completion date: Jan 2016 --> Jan 2017
- |||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Metastases: Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas (clinicaltrials.gov) - Mar 8, 2015
P2, N=136, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- Trial primary completion date: Cytogenetic and Molecular Genetic Studies in Bone Sarcomas (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=1, Suspended, Sponsor: Memorial Sloan Kettering Cancer Center.
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2010 --> Dec 2015
- || carotuximab IV (ENV-105) / Kairos Pharma
Trial primary completion date, Combination therapy, Metastases: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 7, 2015
P1b, N=81, Recruiting, Sponsor: Tracon Pharmaceuticals Inc.
Trial primary completion date: Dec 2010 --> Dec 2015 Trial primary completion date: Mar 2015 --> Jun 2015
- sirolimus / Generic mfg.
Trial primary completion date, Combination therapy: Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (clinicaltrials.gov) - Mar 7, 2015
P1, N=24, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Dec 2014 --> Aug 2014
- | luminespib (AUY922) / Ligand
Enrollment change, Stroma: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Mar 7, 2015
P2, N=24, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Dec 2014 --> Aug 2014 N=34 --> 24
- HEOR: Functional Outcomes and HRQoL in Upper-extremity Sarcoma Patients After Limb Salvage (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=70, Not yet recruiting, Sponsor: Helsinki University Central Hospital
- |||||||||| Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
New P2/3 trial, Metastases: Act.In.Sarc: NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall (clinicaltrials.gov) - Mar 7, 2015
P2/3, N=180, Recruiting, Sponsor: Nanobiotix
- |||| bendamustine / Generic mfg.
Enrollment open, Trial primary completion date: Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma (clinicaltrials.gov) - Mar 7, 2015
P2, N=61, Recruiting, Sponsor: University of Washington
N=34 --> 24 Suspended --> Recruiting | Trial primary completion date: Jan 2015 --> Feb 2016
- Enrollment closed, Surgery: TOMOREP: Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma (clinicaltrials.gov) - Mar 5, 2015
P2, N=44, Active, not recruiting, Sponsor: Institut Bergonié
Suspended --> Recruiting | Trial primary completion date: Jan 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Trial primary completion date: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Mar 5, 2015
P1/2, N=6, Recruiting, Sponsor: Isofol Medical AB
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Oct 2015
- Aplidin (plitidepsin) / PharmaMar, Roche
Trial primary completion date, Metastases: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial (clinicaltrials.gov) - Mar 5, 2015
P2, N=24, Terminated, Sponsor: Institut Bergoni
Trial primary completion date: Jul 2015 --> Oct 2015 Trial primary completion date: Dec 2013 --> Dec 2015
- Calsed (amrubicin) / Sumitomo Pharma, BMS
Trial primary completion date, Metastases: ARSARC-PI-0010: Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 5, 2015
P2, N=30, Active, not recruiting, Sponsor: University of Utah
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Jan 2015 --> Jan 2017
- ||||| Votrient (pazopanib) / Novartis, BeiGene
New P2 trial: Pazopanib for Treating Uterine Leiomyosarcoma (clinicaltrials.gov) - Mar 5, 2015
P2, N=51, Not yet recruiting, Sponsor: Gynecologic Oncology Group
- | Lartruvo (olaratumab) / Eli Lilly
New P1 trial, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Mar 5, 2015
P1, N=18, Not yet recruiting, Sponsor: Eli Lilly and Company
- Trial completion, Enrollment change: A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas (clinicaltrials.gov) - Mar 5, 2015
P=N/A, N=15, Completed, Sponsor: City of Hope Medical Center
Trial primary completion date: Jan 2015 --> Jan 2017 Active, not recruiting --> Completed | N=30 --> 15
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 3, 2015
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=30 --> 15 Trial primary completion date: Feb 2015 --> Sep 2015
- Onureg (azacitidine oral) / BMS, Istodax (romidepsin) / Astellas, BMS
Trial primary completion date, Combination therapy, Metastases: A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma (clinicaltrials.gov) - Mar 2, 2015
P1, N=39, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Zokinvy (lonafarnib) / Eiger
Trial primary completion date: Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide (clinicaltrials.gov) - Mar 2, 2015
P1, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- Clinical: 18F-FES PET/CT in Imaging Patients With Desmoid Tumors (clinicaltrials.gov) - Mar 2, 2015
P=N/A, N=10, Not yet recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- || CC-115 / BMS
Enrollment closed, Trial primary completion date, Metastases: Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. (clinicaltrials.gov) - Mar 2, 2015
P1, N=144, Active, not recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Feb 2016
- Clinical: Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=150, Enrolling by invitation, Sponsor: Edward Hospital
- Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical: Tocilizumab for KSHV-Associated Multicentric Castleman Disease (clinicaltrials.gov) - Feb 27, 2015
P2, N=17, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Feb 2016 Trial primary completion date: Jul 2015 --> Jul 2016
- irinotecan / Generic mfg., sorafenib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors (clinicaltrials.gov) - Feb 27, 2015
P1, N=17, Completed, Sponsor: HMeany
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Completed | N=24 --> 17 | Trial primary completion date: Aug 2014 --> Jan 2015
- luminespib (AUY922) / Ligand, sunitinib / Generic mfg.
Trial primary completion date, Stroma, Metastases: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients (clinicaltrials.gov) - Feb 26, 2015
P2, N=25, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Recruiting --> Completed | N=24 --> 17 | Trial primary completion date: Aug 2014 --> Jan 2015 Trial primary completion date: Oct 2014 --> May 2015
- |||| Trial primary completion date: ARST0531: Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma (clinicaltrials.gov) - Feb 26, 2015
P3, N=481, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2014 --> May 2015 Trial primary completion date: Jan 2015 --> Sep 2014
- ||| Gilotrif (afatinib) / Boehringer Ingelheim
New P1 trial, Monotherapy, Pan tumor: Trial of Afatinib in Pediatric Tumours (clinicaltrials.gov) - Feb 26, 2015
P1, N=60, Not yet recruiting, Sponsor: Boehringer Ingelheim
- Trial primary completion date: Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=3000, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Trial primary completion date: Jan 2015 --> Sep 2014 Trial primary completion date: Jun 2015 --> Jun 2016
- dimethyl fumarate / Generic mfg., temozolomide / Generic mfg.
Enrollment open: Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Feb 24, 2015
P1, N=23, Recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial termination, Metastases: Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma (clinicaltrials.gov) - Feb 23, 2015
P1/2, N=29, Terminated, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Completed --> Terminated; Drug availability issues
- New P1 trial, Surgery: Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery (clinicaltrials.gov) - Feb 23, 2015
P1, N=21, Not yet recruiting, Sponsor: Blaze Bioscience Inc.
- | inhaled lipid cisplatin (ILC) / Eleison Pharma
Enrollment closed, Trial primary completion date: Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma (clinicaltrials.gov) - Feb 23, 2015
P2, N=50, Active, not recruiting, Sponsor: Eleison Pharmaceuticals LLC.
Completed --> Terminated; Drug availability issues Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jan 2016
- ||| Kisqali (ribociclib) / Novartis, siremadlin (HDM201) / Novartis
Combination therapy: Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma (clinicaltrials.gov) - Feb 20, 2015
P1/2, N=86, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jan 2016 N=59 --> 86
- ||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Metastases: YonSar: Efficacy and Safety of Trabectedin (Yondelis (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=100, Recruiting, Sponsor: PharmaMar, Spain
- ||||| Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 20, 2015
P2, N=188, Not yet recruiting, Sponsor: GlaxoSmithKline
- | conatumumab (AMG 655) / Amgen
Enrollment closed, Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 20, 2015
P2, N=12, Active, not recruiting, Sponsor: Amgen
N=59 --> 86 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
- | Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
Trial completion, Enrollment change: NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity (clinicaltrials.gov) - Feb 20, 2015
P1, N=22, Completed, Sponsor: Nanobiotix
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015 Recruiting --> Completed | N=30 --> 22
- || Trial primary completion date, Stroma: Symptom Inventory for Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=188, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=30 --> 22 Trial primary completion date: Jul 2015 --> Jul 2016
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial suspension, Trial primary completion date: Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma (clinicaltrials.gov) - Feb 19, 2015
P2, N=49, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2016 Active, not recruiting --> Suspended | Trial primary completion date: Feb 2015 --> Feb 2016
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Combination therapy, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Feb 19, 2015
P1/2, N=204, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Suspended | Trial primary completion date: Feb 2015 --> Feb 2016 N=160 --> 204 | Not yet recruiting --> Suspended
- | Stivarga (regorafenib) / Bayer
New P2 trial, Stroma, Metastases: ALT GIST: A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (clinicaltrials.gov) - Feb 19, 2015
P2, N=240, Not yet recruiting, Sponsor: Australasian Gastro-Intestinal Trials Group
- ||||| MV-NIS / Vyriad
New P2 trial: MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer (clinicaltrials.gov) - Feb 19, 2015
P2, N=134, Not yet recruiting, Sponsor: Mayo Clinic
- Enrollment status, Phase classification, Enrollment change: Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases (clinicaltrials.gov) - Feb 19, 2015
P0, N=310, Enrolling by invitation, Sponsor: National Cancer Institute (NCI)
N=160 --> 204 | Not yet recruiting --> Suspended Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P0 | N=500 --> 310
- || Enrollment closed: Treatment of Social Competence After Traumatic Brain Injury (clinicaltrials.gov) - Feb 12, 2015
P=N/A, N=248, Active, not recruiting, Sponsor: Craig Hospital
Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P0 | N=500 --> 310 Recruiting --> Active, not recruiting
- lapatinib / Generic mfg.
Surgery: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (clinicaltrials.gov) - Feb 12, 2015
P=N/A, N=33, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Jun 2016
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Feb 12, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2015 --> Jun 2016 Trial primary completion date: Mar 2015 --> Aug 2015